Summary of project PR000922

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000922. The data can be accessed directly via it's Project DOI: 10.21228/M8HH5M This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Project ID: PR000922
Project DOI:doi: 10.21228/M8HH5M
Project Title:Metabolomics analysis of serum samples from patients during 2 years of IAT trial, double blind placebo controled study
Project Type:Study the changes produced by the use of AIT treatment or placebo
Project Summary:47 patients were enrolled in a double-blind, placebo-controlled, multicenter trial using with GRAZAX® (Phleum pretense) during 2 years of therapy (T2). Immunological assays such as sIgE, sIgG4 and ISAC were carried out to the 31 patients who finished the trial. Additionally, serum and PBMCs samples from these samples were analyzed by metabolomics and transcriptomics, respectively. Based on their sensitization level, 22 patients were grouped in Mono and Poli groups, excluding epithelial allergic patients. Individuals were studied based on their treatment in Active and Placebo and their sensitization level.
Institute:Institute of Applied Molecular Medicine;The Centre of Metabolomics and Bioanalysis
Last Name:Barber Hernández
First Name:Domingo
Address:Avda. Monteprincipe s/n 28668 Boadilla del Monte, Madrid, España
Email:domingo.barberhernandez@ceu.es
Phone:Tlf: 91 372 47 00 ext. 4662

Summary of all studies in project PR000922

Study IDStudy TitleSpeciesInstituteAnalysis
(* : Contains Untargted data)
Release
Date
VersionSamplesDownload
(* : Contains raw data)
ST001369 Grass pollen sublingual immunotherapy treatment induces transcriptomic and metabolic changes due to AIT treatment Homo sapiens Institute of Applied Molecular Medicine;The Centre of Metabolomics and Bioanalysis MS* 2020-09-29 1 44 Uploaded data (2.5G)*
  logo